KEYTRUDA plus Padcev improves survival for bladder cancer patients
On Thursday, Jefferies analyst Miyabi Yamakita upgraded Kissei Pharmaceutical (TADAWUL:2070) Co Ltd (4547:JP) stock rating from Hold to Buy, with an increased price target set at JPY5,000, up from the previous JPY3,700. The upgrade reflects confidence in the company’s current product momentum, its shareholder returns, and the progress within its development pipeline.
The positive outlook from Jefferies is supported by several key factors. According to the analyst, the pharmaceutical company’s existing products are showing strong momentum, and it is expected to maintain this trajectory. Additionally, the firm’s pipeline is improving, which further justifies the upgrade.
The analyst highlighted that the downside risks for Kissei Pharmaceutical are limited due to a variety of reasons. Notably, the company does not face any major patent expirations until at least 2030, which provides a stable outlook for its product portfolio. Moreover, the company has low-risk late-stage assets, which suggests a lower likelihood of setbacks in development and potential regulatory approvals.
Another aspect contributing to the positive assessment is the anticipation of shareholder value through foreseeable buybacks and a stable dividend payout ratio. This approach to capital distribution is often seen as a sign of a company’s confidence in its financial stability and future prospects.
Lastly, Jefferies has raised its peak sales estimates for Kissei’s existing products and pipeline, indicating an expectation for increased revenue generation in the future. This revised estimate takes into account the potential market performance and demand for the company’s pharmaceutical offerings.
Investors and market watchers will likely keep a close eye on Kissei Pharmaceutical’s performance, as the company continues to execute its strategy and capitalize on its strong product lineup and promising pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.